STOCK TITAN

Traws Pharma narrows Q3 2026 net loss to $3.55M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Traws Pharma, Inc. (TRAW) reported a third-quarter 2026 net loss of $3.547 million, versus $3.962 million a year earlier; revenue was $0 in both periods. For the nine months ended September 30, 2026, revenue was $0 versus $2.790 million in 2025, and net results were a $14.864 million loss versus $16.613 million of income. Cash and equivalents were $2.338 million at September 30, 2026, versus $3.820 million at December 31, 2025.

In the final 92-subject Phase 2a study, median time to sustained symptom resolution was 13.5 days with ratutrelvir versus 14.5 days with PAXLOVID in eligible subjects. Treatment-related adverse events occurred in 1 of 32 ratutrelvir-treated patients and 4 of 30 PAXLOVID-treated patients; no viral rebound was reported through Day 28. Among 30 PAXLOVID-ineligible subjects, median symptom resolution was 14 days, with no treatment-related adverse events reported. Traws intends to discuss an FDA registration strategy for high-risk adults ineligible for PAXLOVID, including a potential adaptive Phase 2b/Pivotal program and Fast Track designation.

For tivoxavir marboxil, the tablet bridging study achieved its objectives and toxicology retesting is complete; Traws expects to resubmit an updated toxicology package in Q4 2026. TXM also has a current FDA clinical hold.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • Moderate pointThird-quarter net loss narrowed to $3.547 million from $3.962 million.

Negative

  • Major pointNine-month net results shifted to a $14.864 million loss from $16.613 million of income.
  • Moderate pointNine-month revenue was $0, compared with $2.790 million in 2025.

Filing Explained

The balance sheet reports common shares issued and outstanding rising from 9,067,774 on December 31, 2025, to 15,375,595 on September 30, 2026; for holders whose share count did not change, the larger total reduces their percentage ownership.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter revenue $0 Three months ended September 30, 2026; $0 in 2025
Third-quarter net loss $3.547 million loss Three months ended September 30, 2026; $3.962 million loss in 2025
Nine-month revenue $0 Nine months ended September 30, 2026; $2.790 million in 2025
Nine-month net result $14.864 million loss Nine months ended September 30, 2026; $16.613 million net income in 2025
Nine-month operating loss $14.915 million loss Nine months ended September 30, 2026; $10.507 million loss in 2025
Cash and cash equivalents $2.338 million At September 30, 2026; $3.820 million at December 31, 2025
Median time to sustained symptom resolution 13.5 days vs. 14.5 days Ratutrelvir vs. PAXLOVID in eligible subjects
Treatment-related adverse events 1 of 32 vs. 4 of 30 patients Ratutrelvir-treated patients vs. PAXLOVID-treated patients
Mpro (3CL protease) inhibitor medical
"small molecule Mpro (3CL protease) inhibitor"
ritonavir-free medical
"once-daily, ritonavir-free oral antiviral"
adaptive Phase 2b/Pivotal program medical
"potential adaptive Phase 2b/Pivotal program"
Fast Track designation regulatory
"and Fast Track designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
CAP-dependent endonuclease inhibitor medical
"small molecule CAP-dependent endonuclease inhibitor"
A cap-dependent endonuclease inhibitor is an antiviral drug that blocks a viral enzyme the virus uses to snip and reuse short pieces of host RNA to start making its own proteins; without that “snipping” step the virus cannot efficiently copy itself. For investors, these drugs matter because they represent a targeted mechanism of action that can shorten illness and reduce viral spread, potentially creating new treatment markets but also raising issues of resistance, dosing benefits, and regulatory review.
clinical hold regulatory
"including the current FDA clinical hold"
A clinical hold is an order from a drug or medical-device regulator to stop or suspend a clinical trial or development activity because of safety concerns, inadequate study plans, or incomplete data. Think of it like a referee pausing a game until rules or safety issues are resolved; investors care because a hold can delay approval, increase costs, create uncertainty about a product’s future, and often affects a company’s valuation until the issues are addressed.
Revenue $0 $0 in the third quarter of 2025
Net loss $3.547 million loss $3.962 million loss in the third quarter of 2025
Nine-month revenue $0 $2.790 million in 2025
Nine-month net result $14.864 million loss $16.613 million net income in 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Traws Pharma report about ratutrelvir’s Phase 2a results?

In the final 92-subject study, median time to sustained symptom resolution was 13.5 days with ratutrelvir versus 14.5 days with PAXLOVID in eligible subjects. Treatment-related adverse events occurred in 1 of 32 ratutrelvir-treated patients and 4 of 30 PAXLOVID-treated patients, with no viral rebound through Day 28. Among 30 PAXLOVID-ineligible subjects, median symptom resolution was 14 days and no treatment-related adverse events were reported.

What FDA strategy does Traws Pharma plan to discuss for ratutrelvir?

Traws intends to discuss a registration strategy for high-risk adults ineligible for PAXLOVID, including a potential adaptive Phase 2b/Pivotal program and Fast Track designation.

How much cash did Traws Pharma have at September 30, 2026?

Traws reported $2.338 million in cash and cash equivalents at September 30, 2026, compared with $3.820 million at December 31, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001130598 0001130598 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

Traws Pharma, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-36020   22-3627252
(State or Other Jurisdiction
of Incorporation or Organization)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

12 Penns Trail

Newtown, PA 18940
(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $.01 per share TRAW The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

The information provided below in “Item 7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K (this “Current Report”) regarding the Earnings Release is incorporated by reference into this Item 2.02.

 

Item 7.01 Regulation FD Disclosure.

 

On November 16, 2026, Traws Pharma, Inc. (the “Company”) issued a press release (the “Earnings Release”) announcing its financial results for the quarter ended September 30, 2026, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”) and incorporated herein by reference.

 

The information set forth under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

 

Forward-Looking Statements

 

This Current Report, including Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

 

Forward-looking statements in this Current Report, including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company’s business and the accuracy of the forward-looking statements contained herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated November 16, 2026
104   Cover Page Interactive Data File (embedded within the inline XBRL Document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026 TRAWS PHARMA, INC.
     
  By: /s/ Charles Parker
    Charles Parker
    Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

 

Traws Pharma Reports Third Quarter 2026 Financial Results and Provides Business Highlights

 

·Ratutrelvir (COVID): Positive final Phase 2a results support further studies in PAXLOVID®-ineligible patients

 

·Tivoxavir marboxil (TXM, Influenza): Successful completion of tablet bridging study and toxicology retesting support a planned Q4 2026 regulatory resubmission

 

NEWTOWN, PA, November 16, 2026 (GLOBE NEWSWIRE) – Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma,” “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies for COVID-19 and influenza, today reported financial results for the quarter ended September 30, 2026, and provided business highlights for its two antiviral programs: ratutrelvir, a once-daily, ritonavir-free oral antiviral in development for COVID-19, and tivoxavir marboxil (TXM), an investigational long-acting agent for the prevention of seasonal and pandemic influenza.

 

“We have made meaningful progress toward our goal of developing new treatment and prevention options for patients most vulnerable to serious respiratory viral diseases,” said Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. “For ratutrelvir, the final Phase 2a results support its potential as a once-daily, ritonavir-free treatment option for COVID-19, particularly for patients who are ineligible for PAXLOVID®. Our next priority is to engage the FDA on a registration strategy focused on these patients.”

 

“For tivoxavir marboxil, the tablet bridging study achieved its objectives, and toxicology retesting is complete. These results support further evaluation of TXM as a potential once-monthly oral influenza prevention option. We expect to resubmit the updated toxicology package in the fourth quarter,” concluded Dr. Dukes.

 

Recent Business Highlights

 

Ratutrelvir:

 

·Positive Phase 2a results Support Potential as a Ritonavir-Free Treatment Option. The final 92-subject study showed symptom resolution comparable to PAXLOVID®, with fewer treatment-related adverse events and no viral rebound through Day 28. Median time to sustained symptom resolution of 13.5 days with ratutrelvir versus 14.5 days with PAXLOVID® in eligible subjects. Treatment-related adverse events occurred in 1 of 32 ratutrelvir-treated patients versus 4 of 30 treated with PAXLOVID®. In 30 PAXLOVID®-ineligible subjects, median symptom resolution was 14.0 days, with no treatment-related adverse events reported .
·Regulatory Planning for PAXLOVID®-Ineligible Patients. Traws intends to discuss with the U.S. Food and Drug Administration (FDA) a registration strategy for adults at high risk of progression to severe COVID-19 who are ineligible for PAXLOVID®, including a potential adaptive Phase 2b/Pivotal program and Fast Track designation.

 

Tivoxavir Marboxil

 

·Promising New Compressed-Tablet Bridging Study Results. The compressed-tablet formulation provided exposure comparable to the powder-in-capsule formulation and was well tolerated. Consistent with the Company’s earlier modeling, the tablet could support once-monthly dosing. The Company believes the results also support TXM’s use in further efficacy studies, including a planned human influenza challenge study.

 

 

 

 

·TXM Toxicology Re-Testing Results Support Updated Regulatory Submissions. Two independent rat Pig-a gene mutation studies showed no mutagenic effect at doses up to 500 mg/kg, representing an approximately 125-fold margin over planned clinical exposure based on dose. Traws expects to resubmit the updated toxicology package to regulators in the fourth quarter of 2026 .

 

Corporate Update 

 

·Entered into a $50 million common stock purchase agreement with Roth Principal Investments. Under the October 23, 2026 agreement, Traws has the right, but not the obligation, to sell up to $50 million of its common stock to Roth, subject to customary conditions. No shares have been sold under the agreement to date.

 

Third Quarter 2026 Financial Results

 

·Cash and cash equivalents. $2.3 million as of September 30, 2026, compared with $3.8 million as of December 31, 2025.

 

·Research and development expenses. $1.8 million for the third quarter of 2026, compared with $2.3 million for the third quarter of 2025.

 

·General and administrative expenses. $1.8 million for the third quarter of 2026, compared with $1.7 million for the third quarter of 2025.

 

·Net loss. $3.5 million for the third quarter of 2026, compared with $4.0 million for the third quarter of 2025. Net loss per common share, basic and diluted, was $0.18 compared with $0.34 in the prior-year period.

 

·Shares Outstanding: Traws had 15,368,277 shares of common stock outstanding as of November 13, 2026.

 

About Ratutrelvir

 

Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to act broadly against SARS-CoV-2/COVID-19 strains without the need for ritonavir. It has demonstrated in vitro activity against a range of virus strains. Industry data indicate that COVID treatment represents a potential multi-billion dollar market opportunity1. Ratutrelvir has not been approved by any regulatory authority.

 

About Tivoxavir Marboxil

 

Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed for single dose prevention of seasonal influenza and bird flu. It has shown in vitro activity against a range of influenza strains in preclinical studies. Seasonal influenza represents an estimated multi-billion-dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders and inclusion in drug stock piling initiatives2,3, with upside potential from potential pandemic flu outbreaks including H5N1 bird flu. TXM has not been approved by any regulatory authority.

 

About Traws Pharma, Inc.

 

Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to address real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral designed to have potent activity against difficult-to-treat or resistant virus strains. These include viruses associated with seasonal influenza and H5N1 bird flu, as well as negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, and Lassa Fever and viruses associated with COVID-19/Long COVID.

 

 

 

 

Source Information

 

1.Pfizer Inc. annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on February 3, 2026

 

2.Per link

 

3.Traws data on file

 

Third-party products mentioned herein are the trademarks of their respective owners. PAXLOVID® is a registered trademark of Pfizer Inc.

 

Forward-Looking Statements 

 

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, market size, benefits, effectiveness, safety, and the clinical and regulatory plans for ratutrelvir and tivoxavir marboxil, as well as plans for its legacy programs. The Company has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “potential”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including planned discussions with the FDA, potential Fast Track designation, the outcome of Traws’ IND filing with the U.S. Food and Drug Administration (FDA) for tivoxavir marboxil, including the current FDA clinical hold; the success and timing of Traws’ clinical trials; the potential for tivoxavir marboxil or ratutrelvir to gain market acceptance, if and when regulatory approval is obtained, or to become the new standard of care; Traws’ interactions with the FDA, Biomedical Advanced Research and Development Authority (BARDA) and similar foreign regulators; collaborations; market conditions; regulatory requirements and pathways for approval; the extent of the spread and threat of the bird flu; COVID-19; seasonal flu; the Company’s cash projections; Traws’ ability to raise additional capital when needed; and those discussed under the heading “Risk Factors” in Traws’ filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.

 

Contacts

 

Traws Pharma Contact:

 

Charles Parker

Traws Pharma, Inc.
cparker@trawspharma.com

www.trawspharma.com

 

Investor Contact:

 

John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

 

 

 

 

Traws Pharma, Inc.
Condensed Consolidated Statements of Operations (unaudited)

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
Revenue  $—   $—   $—   $2,790,000 
Operating expenses (income):                    
Research and development   1,832,000    2,311,000    9,037,000    7,108,000 
General and administrative   1,770,000    1,744,000    7,283,000    6,189,000 
Other operating income   —    —    (1,405,000)   — 
Total operating expenses, net   3,602,000    4,055,000    14,915,000    13,297,000 
Loss from operations   (3,602,000)   (4,055,000)   (14,915,000)   (10,507,000)
Change in fair value of warrant liability   37,000    (3,000)   93,000    26,656,000 
Other income (loss), net   18,000    96,000    (42,000)   464,000 
Net (loss) income  $(3,547,000)  $(3,962,000)  $(14,864,000)  $16,613,000 
Net (loss) income attributable to common stockholders, basic and diluted  $(3,063,000)  $(3,035,000)  $(12,540,000)  $12,263,000 
Weighted-average shares of common stock outstanding, basic   17,044,826    8,818,859    14,539,956    7,851,515 
Net (loss) income per share of common stock, basic  $(0.18)  $(0.34)  $(0.86)  $1.56 
Weighted-average shares of common stock outstanding, diluted   17,044,826    8,818,859    14,539,956    8,006,487 
Net (loss) income per share of common stock, diluted  $(0.18)  $(0.34)  $(0.86)  $1.53 
Net (loss) income attributable to Series C Preferred stockholders, basic and diluted  $(484,000)  $(927,000)  $(2,324,000)  $4,350,000 
Weighted-average shares of Series C Preferred outstanding, basic and diluted   6,737    6,737    6,737    6,962 
Net (loss) income per share of Series C Preferred, basic and diluted  $(71.84)  $(137.60)  $(344.96)  $624.82 

 

 

 

 

Traws Pharma, Inc.
Condensed Consolidated Balance Sheets (unaudited)

 

   September 30,   December 31, 
   2026   2025 
Assets          
Current assets:          
Cash and cash equivalents  $2,338,000   $3,820,000 
Tax incentive and other receivables   2,195,000    3,794,000 
Prepaid expenses and other assets   444,000    365,000 
Total current assets   4,977,000    7,979,000 
Property and equipment, net   5,000    7,000 
Intangible assets, net   2,398,000    2,527,000 
Other assets   142,000    104,000 
Total assets  $7,522,000   $10,617,000 
Liabilities and stockholders’ deficit          
Current liabilities:          
Accounts payable  $6,651,000   $5,653,000 
Accrued expenses and other liabilities   2,991,000    5,493,000 
Total current liabilities   9,642,000    11,146,000 
Warrant liabilities   8,000    100,000 
Total liabilities   9,650,000    11,246,000 
           
Commitments and contingencies (Note 5)          
           
Stockholders’ deficit:          
Series C Preferred stock, $0.01 par value, 5,000,000 shares authorized, 7,440 shares issued and 6,737 shares outstanding at September 30, 2026 and December 31, 2025   —    — 
Common stock, $0.01 par value, 250,000,000 shares authorized, 15,375,595 and 9,067,774 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively   153,000    90,000 
Additional paid-in capital   652,574,000    639,259,000 
Accumulated deficit   (654,848,000)   (639,984,000)
Accumulated other comprehensive (loss) income   (7,000)   6,000 
Total stockholders’ deficit   (2,128,000)   (629,000)
Total liabilities and stockholders’ deficit  $7,522,000   $10,617,000 

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading